Hatem Amer, M.D.

This study is being done to gather information regarding your health in relation to your composite tissue transplant. We would like to use your medical records (both existing and future) to study the health of patients who will receive or have received a composite tissue transplant. This research would include looking at your demographic information, cause of initial injury, laboratory test results and medical exams relating to your pre and post transplant care, and your mental well-being before and after transplant.

The purpose of this study is to evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult and pediatric patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient is post renal transplantation. Treatment for FSGS is considered unsuccessful if the patient is unresponsive to standard therapy (e.g., at least 8 weeks of corticosteroids) and fails to achieve complete or partial remission. A standard treatment is considered not well tolerated if the patient experiences severe side effects without providing an acceptable level of clinical benefit.

The purpose of this study is to evaluate treatment of BK polyomavirus with the use of Brincidofovir. 

The purpose of this study is to to determine whether or not prior living kidney donors have an increased risk of bone fractures. The study will also determine bone structure and health in prior living donors as compared to matched controls.  

We will determine if living kidney donors are at increased risk of bone disease and fractures following kidney donation. This information will be valuable in informing future kidney donors of the risks of donation and in devising treatments, such as administration of vitamin D analogs like calcitriol, to prevent such complications.

The purpose of this study is test the hypothesis that plasmapheresis plus rituximab prior to or shortly after kidney transplantation can prevent recurrent Focal Segmental Glomerulosclerosis (FSGS) in children and adults.